[{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Epoetin Alfa","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Blau Farmaceutica \/ Blau Farmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"Blau Farmaceutica \/ Blau Farmaceutica"}]

Find Clinical Drug Pipeline Developments & Deals by Blau Farmaceutica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.

                          Brand Name : rHuEPO

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 25, 2022

                          Lead Product(s) : Erythropoietin EPO

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Recipient : JSR Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank